<DOC>
	<DOCNO>NCT00459550</DOCNO>
	<brief_summary>A study investigate safety tolerability single multiple intravenous administration GSK933776 patient Alzheimer 's Disease .</brief_summary>
	<brief_title>A Clinical Study Assess Single Repeat Doses New Medication ( GSK933776 ) Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Male female subject clinical diagnosis probable Alzheimer 's disease Subject mild AD Mini Mental State Examination ( MMSE ) score 1826 inclusive screen visit . Age 55 80 year . Female subject must postmenopausal surgically sterile . Male subject whose partner childbearing potential menopausal &lt; 2 year must use adequate form contraception . Subject ability comply procedure cognitive test &amp; fluent language use administration cognitive test . Subject life ( substantial period contact ) permanent caregiver willing oversee subject 's compliance protocolspecified procedure study medication , report subject 's status . Subject provide full write informed consent prior performance protocolspecified procedure . Caregiver provide full write informed consent his/her behalf prior performance protocolspecified procedure . Exclusion criterion : History and/or evidence central nervous system ( CNS ) disorder could interpret cause dementia . Subjects currently live nurse home . Subjects unable provide inform consent due cognitive status Screening brain MRI 1 follow condition : consistent AD , evidence CNS condition , show minimal vascular change , 3 microhaemorrhage lesion . Focal finding neurological exam . Any contraindication lumbar puncture . History evidence significant psychiatric illness schizophrenia bipolar affective disorder significant neurological disease AD . TIA/stroke last 3 year , type 1 type 2 diabetes mellitus , active cardiovascular disease , uncontrolled risk factor stroke . Current recent drug alcohol abuse dependence recent remote history could contribute factor dementia . History evidence significant autoimmune disease disorder . History seizure ( exclude febrile seizure childhood ) , current blood clot bleed disorder condition predispose ( e.g . cancer ) , current clinically significant systemic illness significant infection within 30 day likely result deterioration subject 's condition affect subject 's safety study . History cerebral amyloid antiopathy and/or hypertensive cerebral haemorrhage know risk intercerebral haemorrhage/microhaemorrhage . Treatment cholinesterase inhibitor , memantine selegiline unless therapy institute least 3 month prior administration GSK933776 , stable dosage 2 month prior regimen continue duration trial subject free clinically significant side effect attributable drug . Subjects discontinue cholinesterase inhibitor , memantine , cognitive enhance agent , drug potentially affect cognition 60 day prior screen . Unless maintain stable dose regimen least 30 day prior screen , medication potential affect cognition . Use drug platelet antiaggregant anticoagulant property ( exclude use aspirin 325 mg/day less ) , anticonvulsants seizure narcotic medication . History current chronic use systemic steroid immunosuppressant . Prior participation clinical investigation involve therapeutic monoclonal antibody proteins derived monoclonal antibody investigation treatment use experimental medication AD investigational medication device within 60 day prior screen within 5 halflives use medication prior screening , whichever longer . Contraindications MRI : pacemaker , aneurysm clip , artificial heart valve , metal foreign body , claustrophobia , etc . Smoking 20 cigarette equivalent per day .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>First Time Human ( FTIH ) Study</keyword>
</DOC>